Medical Device | February 28, 2022
Europe clears blood test to predict Alzheimer’s disease
It is the first approved blood test that can predict likely progression to Alzheimer's Disease up to six years in advance
It is the first approved blood test that can predict likely progression to Alzheimer's Disease up to six years in advance
The collaboration will accelerate the testing of GliaPharm’s lead molecules in preclinical models of Alzheimer’s disease and further the development of neuroimaging biomarkers
Launching in 2022, its availability will be expanded to the global market
Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
Strengthening focus in Alzheimer's disease and neuroscience pipeline
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
Subscribe To Our Newsletter & Stay Updated
